Close Menu

NEW YORK — Genetron Health on Thursday reported a 40 percent year-over-year rise in revenues for the second quarter on strong sales from its cancer diagnosis and monitoring operations, which include lab-developed tests (LDTs) and in vitro diagnostics (IVDs).

Beijing-based Genetron, which went public in the US in June to raise $235.0 million, posted second quarter revenues of RMB101.7 million ($14.6 million) versus RMB72.5 million in the year-ago period.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.